Rapid influenza diagnostic tests only detect the new H1N1 strain and other flu viruses between 40 and 69 percent of the time, according to a pilot study by CDC researchers.
The firms will develop tests to run on Enigma's ML platform. As part of the alliance, GSK will make an equity investment in the molecular diagnostics startup.
The firm has been cleared by FDA to include data from two studies that shows its Respiratory Viral Panel can be an effective aid in detecting the virus.
USPTO Publishes One Patent, Seven Patent Applications Related to RNAi
The CDC's assay will run on ABI's 7500 Fast Dx Real-Time PCR instrument or the research use only 7500 Real-Time PCR instrument.
The study, begun last year, will take longer than the June 2009 timeframe projected late last year. It calls for the NIH to analyze the ability of the Biosafety Level 4 lab to contain 13 toxins to be studied there, and ensure it can run safely.
Oregon Health and Science University will use a $41M grant to start a regional biodefense and infectious disease center.
The pact builds on an existing relationship between the firms to develop an influenza molecular diagnostic assay for use with a HandyLab instrument.
USPTO Publishes Six RNAi-Related Patent Applications
The Athens, Ohio-based firm licensed novel yeast-based virus cloning technology that will be used for HIV pharmacogenomics and other disease areas.
As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.
BBC News says the uncertainty over Brexit is affecting science funding in the UK.
A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.
In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.